Efgartigimod for immune checkpoint inhibitor induced polyradiculoneuropathy and cardiomyopathy: A case report

Larroquette M, Domblides C, Lefort F, Lasserre M, Quivy A, Sionneau B, Bertolaso P, Gross-Goupil M, Ravaud A and Daste A: Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. Eur J Cancer 158: Oct 13, 2021 (Epub ahead of print).

Lee DJ, Lee HJ Jr, Farmer JR and Reynolds KL: Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Cardiol Rep. 23(98)2021.PubMed/NCBI View Article : Google Scholar

Farina A, Villagrán-García M, Vogrig A, Zekeridou A, Muñiz-Castrillo S, Velasco R, Guidon AC, Joubert B and Honnorat J: Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol. 23:81–94. 2024.PubMed/NCBI View Article : Google Scholar

Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V and Salgia R: Immune checkpoint inhibitor induced myocarditis with myositis/myasthenia gravis overlap syndrome: A systematic review of cases. Oncologist. 26:1052–1061. 2021.PubMed/NCBI View Article : Google Scholar

Arora P, Talamo L, Dillon P, Gentzler RD, Millard T, Salerno M, Slingluff CL Jr and Gaughan EM: Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: An institutional case series. Cardiooncology. 6(21)2020.PubMed/NCBI View Article : Google Scholar

Raikhelkar J and Uriel N: Immune checkpoint inhibitor myocarditis. Curr Opin Cardiol. 34:303–306. 2019.PubMed/NCBI View Article : Google Scholar

Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, et al: Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 128:4372–4386. 2018.PubMed/NCBI View Article : Google Scholar

Campbell M, Rodriguez-Hernandez A, Rizvi Z, Swerdloff M, Zakin E and Faktorovich S: Efgartigimod for pembrolizumab-induced myasthenia gravis refractory to standard therapy (P1-8.006). Neurology. 100 (Suppl 17)(S2319)2023.

Aids to the investigation of peripheral nerve injuries. JAMA. 122(266)1943.

Katz S, Ford AB, Moskowitz RW, Jackson BA and Jaffe MW: Studies of illness in the aged. The index of adl: A standardized measure of biological and psychosocial function. JAMA. 185:914–919. 1963.PubMed/NCBI View Article : Google Scholar

Merkies ISJ, Schmitz PIM, Van Der Meché FGA, Samijn JPA and Van Doorn PA: Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve. 25:370–377. 2002.PubMed/NCBI View Article : Google Scholar

Jin L, Xu K, Liang Y, Du P, Wan S and Jiang C: Effect of hyaluronic acid on cytokines and immune cells change in patients of knee osteoarthritis. BMC Musculoskelet Disord. 23(812)2022.PubMed/NCBI View Article : Google Scholar

Okada K, Seki M, Yaguchi H, Sakuta K, Mukai T, Yamada S, Oki K, Nakahara J and Suzuki S: Polyradiculoneuropathy induced by immune checkpoint inhibitors: A case series and review of the literature. J Neurol. 268:680–688. 2021.PubMed/NCBI View Article : Google Scholar

Salim A, Tapia Rico G, Shaikh A and Brown MP: A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies. Expert Opin Biol Ther. 21:1237–1251. 2021.PubMed/NCBI View Article : Google Scholar

Seki M, Kitano S and Suzuki S: Neurological disorders associated with immune checkpoint inhibitors: An association with autoantibodies. Cancer Immunol Immunother. 71:769–775. 2022.PubMed/NCBI View Article : Google Scholar

Won T, Song EJ, Kalinoski HM, Moslehi JJ and Čiháková D: Autoimmune myocarditis, old dogs and new tricks. Circ Res. 134:1767–1790. 2024.PubMed/NCBI View Article : Google Scholar